Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients

68 subjects randomized into two study groups: 34 subjects consume the supplement of the study and 34 control consume the supplement IMPACT.

Intervention period will be 10 days before surgery . The consume amount is 400 ml/ day. The Subjects were stratified according to tumor location ( larynx and oral cavity and oropharynx, hypopharynx) and disease stage (early and advanced).

Inclusion criteria

• Men and women >18 years
• Patients with histologically confirmed squamous cell cancer of the oropharynx, hypopharynx , larynx and oral cavity and candidates for neoplastic surgery (undergoing surgery)
• Adequate cultural level and understanding for the clinical trial. and agree to participate voluntarily in the study and give written informed consent
• Patients who do not participate in other clinical trials

Exclusion criteria

• Patients with an active infectious process at the time of the study.
• Patients who have undergone radiotherapy / chemotherapy prior to surgery.
• Subjects diagnosed with Type I Diabetes Mellitus
• Subjects who used oral hypoglycemic agents or insulin.
• Patients with severe kidney disease, heart, respiratory or liver.
• Patients with autoimmune diseases or immunosuppressive drugs used.
• Subjects with dementia, mental illness or diminished cognitive function.
• Subjects who refuse oral supplements.
• Subjects who consume vitamin supplements or artificial nutrition, and which can not be suspended at least 1 week before the study and do not accept to suspend it during the study.
• Subjects with morbid obesity (BMI ≥ 40 kg / m2).
• Pregnant or breastfeeding
• Patients diagnosed with epidermoid carcinoma T1 glottic, cordectomy candidate.